The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Venlo, The Netherlands, July 02, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the second quarter 2024....
QIAGEN (QGEN) supports the new TB screening guidelines from AAP, recommending IGRA tests like QFT-Plus to screen at-risk children of all ages....
American Academy of Pediatrics in the United States now recommends IGRA tests like QuantiFERON-TB Gold Plus to screen at-risk children of all ages // New recommendation joins trend of U.S. tuberculosi...
QIAGEN's (QGEN) latest QCI Interpret release improves the performance of high-throughput NGS labs....
QIAGEN (QGEN) launches new QIAcuity dPCR assays for microbial applications, enhancing infectious disease research and surveillance....
Hosts Capital Markets Day event in New York to outline strategy anchored by sharpened focus on growth pillars set to drive about 7% CER sales CAGR from 2024-2028 // Targeting at least 31% CER adjusted...
Latest QCI Interpret release enhances performance of high-throughput NGS labs, improving turn-around time, diagnostic yield and quality of results // New features include bulk variant assessment, flag...
ESG commitments recognized as strategic business investments bringing value to stakeholders, including customers and employees // Environment: 15% reduction in Scope 1 and 2 emissions in 2023 through ...
35 new wet-lab tested digital PCR Microbial DNA Detection Assays on research platform GeneGlobe target a wide range of pathogens causing tropical diseases, sexually transmitted and urine tract infecti...